New hope for slowing NF2 tumor growth in groundbreaking trial
NCT ID NCT04374305
Summary
This study is testing two different drugs, brigatinib and neratinib, to see if they can slow or shrink tumors in people with a genetic condition called NF2-related schwannomatosis. About 100 participants with growing tumors will be assigned to receive one of the drugs. The main goal is to see if the drugs can control tumor growth, and participants can be followed for up to 10 years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPENDYMOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Indiana University School of Medicine
Indianapolis, Indiana, 46202, United States
-
Johns Hopkins Hospital
Baltimore, Maryland, 21287, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02115, United States
-
New York University Langone Medical Center
New York, New York, 10016, United States
-
UCLA Medical Center
Los Angeles, California, 90095, United States
-
University of Miami
Miami, Florida, 33136, United States
Conditions
Explore the condition pages connected to this study.